Trial Information

Summary: SWOG E1697: Phase III Randomized Study of Four Weeks of High Dose IFN-a2b in Stage T3 - T4 or N1 (microscopic) Melanoma

You have been asked to participate in this research study because you have malignant melanoma that has been treated with surgery and it is possible that your melanoma might relapse (return). The primary objective of this study is to compare treatment with 4 weeks of high-dose IFN-a2b to observation alone in terms of relapse-free survival, side effects, and quality of life. If you are assigned to receive treatment on this study, it is expected to last for four weeks. All subjects on this study will be asked to have regular medical evaluations for five years. After your active participation is complete, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: May 5, 2008 at 3:17:05 PM